News & Events

3 10, 2024

Join Avance Biosciences at the #1 Immunogenicity & Bioassay Event in the US

2024-10-08T13:22:26+00:00

Avance Biosciences is excited to announce its participation in the upcoming Immunogenicity & Bioassay Summit, taking place from October 15-18, 2024, in Washington, DC. As the premier immunogenicity and bioassay event in the U.S., this summit provides an excellent platform for us to connect with industry [...]

Join Avance Biosciences at the #1 Immunogenicity & Bioassay Event in the US2024-10-08T13:22:26+00:00
3 09, 2024

Avance Biosciences to Attend the 2nd CRISPR-Based Therapy Analytical Development Summit

2024-09-03T18:07:26+00:00

Avance Biosciences is excited to announce its participation in the upcoming 2nd CRISPR-Based Therapy Analytical Development Summit, taking place from September 17-19, 2024, in Boston, MA. This premier event is a key gathering for professionals and innovators in the gene editing and CRISPR fields.[...]

Avance Biosciences to Attend the 2nd CRISPR-Based Therapy Analytical Development Summit2024-09-03T18:07:26+00:00
20 08, 2024

World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England

2024-08-20T13:52:29+00:00

Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel. Exa-cel is the world’s first CRISPR-based gene therapy and the first gene therapy available in Europe for treating severe beta-thalassaemia...

World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England2024-08-20T13:52:29+00:00
6 08, 2024

FDA Approves First T Cell Receptor (TCR) Gene Therapy

2024-08-06T19:21:42+00:00

Tecelra is the first FDA-approved T cell receptor (TCR) gene therapy. The product is an autologous T cell immunotherapy composed of a patient’s own T cells. T cells in Tecelra are modified to express a TCR that targets MAGE-A4, an antigen expressed by cancer cells in synovial sarcoma...

FDA Approves First T Cell Receptor (TCR) Gene Therapy2024-08-06T19:21:42+00:00
31 07, 2024

Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL

2024-07-31T13:47:53+00:00

Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period, according to a recent study...

Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL2024-07-31T13:47:53+00:00
30 04, 2024

Join Avance Biosciences at the 2024 AAPS National Biotechnology Conference

2024-07-16T19:33:35+00:00

Avance Biosciences™ offers top-tier GLP & GMP compliant services in assay development, validation, & sample testing for biopharma. Visit our booth to explore how we support drug discovery, development, & manufacturing with precision & expertise. [...]

Join Avance Biosciences at the 2024 AAPS National Biotechnology Conference2024-07-16T19:33:35+00:00
23 04, 2024

Accelerating Gene and Cell Therapy Innovation: Avance Biosciences at ASGCT 2024

2024-07-16T19:34:01+00:00

Avance Biosciences™ is excited to announce our participation in the American Society of Gene & Cell Therapy (ASGCT) conference, where we’ll be showcasing our advanced services and expertise to propel the future of gene and cell therapy. [...]

Accelerating Gene and Cell Therapy Innovation: Avance Biosciences at ASGCT 20242024-07-16T19:34:01+00:00
16 04, 2024

Join Avance Biosciences™ at the WRIB Conference – May 6-10, 2024

2024-07-16T19:34:47+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Join Avance Biosciences™ at the WRIB Conference – May 6-10, 20242024-07-16T19:34:47+00:00
3 04, 2024

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy

2024-07-13T13:07:32+00:00

CAR T-cell therapies show promise for blood cancers but struggle with solid tumors due to T-cell weakness in tumor microenvironments. Researchers find genetic alterations in cancerous T cells, giving engineered T cells "superpowers" to effectively kill tumors without behaving like cancer cells...

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy2024-07-13T13:07:32+00:00
Go to Top